Long-term persistence, effectiveness, safety, and metabolic impact of bictegravir/emtricitabine/tenofovir alafenamide fixed-dose combination in people living with HIV in the BICTARG cohort
Diego Cecchini, Martín Brizuela, Gastón Copertari, Brenda Bacelar, Cinthia Lamaizon, Macarena Roel, Edgardo Bottaro, Isabel Cassetti · 2026
Read Long-term persistence, effectiveness, safety, and metabolic impact of bictegravir/emtricitabine/tenofovir alafenamide fixed-dose combination in people living with HIV in the BICTARG cohort by Diego Cecchini, Martín Brizuela, Gastón Copertari, Brenda Bacelar, Cinthia Lamaizon, Macarena Roel, Edgardo Bottaro, Isabel Cassetti (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13382524.txt.
Description
Diego Cecchini and colleagues report a 2026 long-term cohort study of a single-pill HIV treatment in Argentina. The pill combines three drugs and is a preferred option under international guidelines. Long-term evidence from everyday practice in Latin America was scarce, though. The cohort is called BICTARG.
The study followed 3,057 people who started the regimen between 2019 and 2022, most of whom had taken HIV treatment before. It tracked how long people stayed on the pill, how many kept the virus suppressed, side effects, and changes in blood sugar and fats at two, three, and four years. Persistence and suppression stayed high over four years in people new to treatment, with no side effects reported in that group.
Catalog record
| CREATOR | Diego Cecchini, Martín Brizuela, Gastón Copertari, Brenda Bacelar, Cinthia Lamaizon, Macarena Roel, Edgardo Bottaro, Isabel Cassetti |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23628 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |